连花清瘟联合西药治疗COVID-19有效性与安全性的更新meta分析
该系统综述与meta分析检索七个中英文数据库,纳入7项研究共916例COVID-19患者,评估连花清瘟联合西药对比对照组的疗效与安全性。结果显示联合组总有效率、胸部CT表现、临床症状改善及发热缩短更优,不良事件与重症转化率更低,但原始研究方法学质量低,结论尚不明确。
要点
- 连花清瘟联合西药可能提高COVID-19总有效率并降低重症转化率。
- 联合组不良事件发生率更低,胸部CT表现及发热等症状改善更优。
- 因纳入研究方法学质量低,该meta分析尚不能得出明确结论。
核心结论
- 连花清瘟联合西药治疗COVID-19可能更有效,但因原始研究方法学质量低且设计不严谨,本meta分析无法得出明确结论。
研究设计与样本
- 系统综述与meta分析,检索七个中英文数据库,纳入随机对照试验或病例对照研究,共7项研究、916例参与者。
主要发现
- 与对照组相比,干预组总有效率OR=2.23(95%CI 1.56, 3.18),不良事件OR=0.42(95%CI 0.18, 0.97)。
- 胸部CT表现OR=1.74(95%CI 1.12, 2.72),重症转化加重率OR=0.47(95%CI 0.30, 0.75),均优于对照组。
- 干预组在改善发热、咳嗽、乏力、胸闷、气短、咳痰等临床症状及缩短发热持续时间方面优于对照组(p<0.05)。
关键数值与推荐
- 总有效率OR=2.23(95%CI 1.56, 3.18)。
- 不良事件OR=0.42(95%CI 0.18, 0.97)。
- 胸部CT表现OR=1.74(95%CI 1.12, 2.72)。
- 重症转化加重率OR=0.47(95%CI 0.30, 0.75)。
- 临床症状改善及发热持续时间缩短的组间比较p<0.05。
临床怎么用
- 在COVID-19治疗中,可考虑连花清瘟联合西药以改善总有效率、胸部CT表现及发热咳嗽乏力等症状。
- 联合用药可能降低不良事件发生率和重症转化加重率,但需结合患者具体情况评估。
- 因证据质量有限,临床决策应谨慎,不宜仅凭本meta分析作出明确推荐。
局限性
- SARS-CoV-2疫情紧急性导致纳入研究方法学质量低、设计不严谨。
- 本meta分析因上述局限无法得出明确结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The traditional Chinese medicine formula Lianhua Qingwen (LQ) combined with western medicine therapy is beneficial to coronavirus disease-19 (COVID-19), but there is still a lack of strong evidence-based. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of LQ combined with western medicine for patients with COVID-19. Seven databases (Chinese and English) were searched by two independent reviewers. Search for relevant keywords such as "Chinese medicine," "Chinese herbal medicine," and "Lianhua Qingwen" in the titles and abstracts of articles retrieved in the databases. Randomized controlled trials or case-control studies that reported sufficient data of participants before and after the intervention were included. Two researchers independently reviewed the studies and extracted the data. Fixed-or random-effect model was used to calculate the overall pooled risk estimates. Forest plots were generated to show pooled results. Seven studies involving 916 participants were included in the meta-analysis. Overall, compared with the control group, the total efficacy (OR = 2.23, 95% CI 1.56, 3.18), adverse events (OR = 0.42, 95% CI 0.18, 0.97), chest computed tomography manifestations (OR = 1.74, 95% CI 1.12, 2.72), and aggravation rate of conversion to severe cases (OR = 0.47, 95% CI 0.30, 0.75) of the intervention group were better. Moreover, the intervention group has an advantage over the control group in improving clinical symptoms (fever, cough, fatigue, chest tightness, shortness of breath, and expectoration) and shortening the fever duration (p < 0.05). Our findings indicate that LQ combined with western medicine may be more effective in treating COVID-19. However, due to the urgency of SARS-CoV-2 outbreaks leading to low methodological quality and not rigorous designs. This meta-analysis cannot draw clear conclusions. PROSPERO registration number: CRD42020190757.
引用
- Li Y, Xiao P, Liu N, et al. Efficacy and Safety of Chinese Medicine Lianhua Qingwen for Treating COVID-19: An Updated meta-Analysis. Front Pharmacol. 2022. PMID: 35721166. doi:10.3389/fphar.2022.888820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。